JATT II Acquisition Corp. Finalizes Merger with Talawar Therapeutics, Securing $285M for Biotech Pipeline
JATT sits 16% above its 52-week low of $10 on elevated volume (23× avg).
Summary
JATT II Acquisition Corp. has entered into a definitive agreement to merge with Talawar Therapeutics, a biotech company focused on immunology and inflammatory diseases, securing $285 million in total funding.
Key Events · M&A and Partnerships · JATT
-
Definitive Business Combination
JATT II Acquisition Corp. (SPAC) will merge with Talawar Therapeutics, an immunology and inflammatory disease biotech. The combined entity will operate as Talawar and trade on Nasdaq under "TLWR."
-
Significant Capital Raise
The merger includes a $225 million oversubscribed Private Investment in Public Equity (PIPE) alongside JATT's $60 million IPO proceeds, totaling $285 million for the combined company.
-
Pipeline Focus
The funding will support Talawar's lead preclinical asset, TALA-125, an anti-IL-13 and anti-IL-18 bispecific antibody for atopic dermatitis, with clinical trials expected to begin in Q1 next year.
-
Strategic Rationale
Talawar chose the SPAC route for speed and certainty to fund its clinical development timeline, aiming for interim Phase 1 data by Q4 2027 and Phase 2b data by H2 2028.
Analysis · JATT · Real Estate & Construction
This filing details the definitive merger agreement between JATT II Acquisition Corp. and Talawar Therapeutics, marking a pivotal transformation for the SPAC into an operating biotech company. The substantial $285 million in combined funding, including a $225 million PIPE, provides critical capital for Talawar's lead asset, TALA-125, and its clinical development. This event significantly de-risks the near-term financial runway for the biotech, allowing it to advance its pipeline with a clear path to key clinical milestones.
At the time of this filing, JATT was trading at $11.63 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $93.4M. The 52-week trading range was $10.00 to $12.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.